The following slides are provided as presented by the author during the live educational activity and are intended for reference purposes only.

If you have any questions, please contact Imedex via email at: cme@imedex.com
Squamous Cell Cancer of the Esophagus
Definitive Chemoradiotherapy

Prof. Florian Lordick
University Cancer Center Leipzig
A Case from Last Week

- 09/2017 Diagnosis in a female, 58 ys, **Esophageal Squamous Cell Cancer**
  Location: **middle third, T3 N+ M0**, 10cm length, stenotic, without airway infiltration

- 10-11/2017 **Cisplatin/5-FU + 60Gy (fr 2Gy)**

- 6/2018: **Recurrence/tumor persistence** in the esophageal wall (in a ’radiogenic stenosis‘).

- Diagnosis with repeated bite-on-bite biopsies

CT Thorax/Abdomen 7 June 2018
A Case from Last Week

To be discussed

• Was the decision for definitive RCTx correct?

• Was the treatment regimen correct? Cisplatin/5-FU + 60Gy (fr 2Gy)

• How to treat local recurrence?
1. Was the Decision for Definitive RCTx Correct?

ESMO Guidelines
Esophageal Cancer

Randomized Trials – Postoperative Mortality

**FRENCH FFCD9102**

- 46 Gy + SURG
- Def. CRTx 66 Gy

**GERMAN**

- 40 Gy + SURG
- Def. CRTx 65 Gy

---


Randomized Trials – Postoperative Mortality

**FRENCH FFCD9102**

90-day mortality 9.3% vs. 0.8%

**GERMAN**

Tx.-rel. mortality 12.8% vs. 3.5%


Contemporary Postoperative Mortality

Scandinavia 2016
NeoRes Study*
Cisplatin/5-FU + 40 Gy → Surgery

90-day mortality (6/78)
8%

*N ESCC 28%, AC 72% included in analysis

Netherlands 2017
Extended CROSS eligibility criteria**
Carbo/Paclitaxel + 41.4 Gy → Surgery

90-day mortality (7/72)
10%

**E SCC 21%, AC 79% included in analysis

QoL post Esophagectomy vs Def. RCTx (FFCD9102)

Physical functioning and fatigue scores were not restored to pre-esophagectomy levels.

Most QoL domains were restored to pre RCTx levels

A Case from Last Week

To be discussed

- Was the decision for definitive RCTx correct?
- Was the treatment regimen correct? Cisplatin/5-FU + 60Gy (fr 2Gy)
- How to treat local recurrence?
Standard versus Higher Radiation Dose

USA INT 0123 (2002)

Standard versus Higher Radiation Dose

China Randomized Controlled Trial, with IMRT (2018)

Conclusion: Chemoradiation with a dose of **50.4 Gy remains standard** for definitive treatment. No evidence of benefit for dose escalation > 50.4 Gy

Xu YZW, et al. ASCO 2018; #4013
Cisplatin-5FU versus FOLFOX + RTx

France - PRODIGE5 / ACCORD17

Cisplatin-5FU x 4 + 50Gy (fr 2Gy)

FOLFOX x 6 + 50Gy (fr 2Gy)

## Better Chemotherapy in Definitive RCTx?

<table>
<thead>
<tr>
<th>Study</th>
<th>Regimen</th>
<th>OS Standard</th>
<th>OS Experimental</th>
<th>HR and P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK SCOPE-1</td>
<td>Cisplatin 60 mg/m² d1 Capecitabine 625 mg/m² 2x/d (d1–21) + 50 Gy/2.0 Gy +/- Cetuximab</td>
<td>Median 25.4 months</td>
<td>Median 22.1 months</td>
<td>HR 1.53 [95% CI 1.03–2.27]; p=0.035</td>
</tr>
<tr>
<td>USA RTOG 0436</td>
<td>Cisplatin (50mg/m²), Paclitaxel (25mg/m²), + 50.4 Gy/1.8 Gy +/- Cetuximab</td>
<td>2 years: 44%</td>
<td>2 years: 45%</td>
<td>HR, 0.90; 95%CI, 0.70-1.16; P = 0.47</td>
</tr>
</tbody>
</table>

**Conclusion:** Chemotherapy with Cisplatin and 5-FU + RTx + ~50 Gy remains standard. No evidence of greater efficacy for any other regimen.

A Case from Last Week

To be discussed

• Was the decision for definitive RCTx correct?

• Was the treatment regimen correct?
  Cisplatin/5-FU + 60Gy (fr 2Gy)

• How to treat local recurrence?
What is the Treatment of Relapse?

ESMO Guidelines
Esophageal Cancer

Probability of complete response
48% for ESCC
(according to CROSS study)

Salvage versus Planned Surgery

**Table:**

<table>
<thead>
<tr>
<th></th>
<th>SALV</th>
<th>NCRS</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-hospital mortality</td>
<td>8.4%</td>
<td>9.3%</td>
<td></td>
</tr>
<tr>
<td>Anastomotic leak rate</td>
<td>17.2%</td>
<td>10.7%</td>
<td>0.007</td>
</tr>
<tr>
<td>3-y-OS</td>
<td>43.3%</td>
<td>40.1%</td>
<td>0.542</td>
</tr>
<tr>
<td>3-y-DFS</td>
<td>39.2%</td>
<td>32.8%</td>
<td>0.232</td>
</tr>
</tbody>
</table>

**Figure:**

- Proportion surviving over time (months).
- HR, 0.939 (95% CI, 0.780 to 1.152, P = .542).

**References:**

Salvage Surgery

- High mortality (16% vs 6%) in low vs high volume centers
- High mortality (28% vs 4%) after > 55Gy radiation

Pre Sano Trial

Selection of patients for a watch-and-wait strategy

- Endoscopy
- Bite-on-bite biopsy
- Endosonography
- Fine needle aspiration
- PET-CA

Clinical Response Evaluation
week 6 and week 12

- Sensitivity 90%
- Specificity 72%

Ongoing Phase II / Phase III Studies

NL  SANO TRIAL

FRANCE  PRODIGE-32  ESOSTRATE FFCD-1401


https://clinicaltrials.gov/ct2/show/NCT02551458
SUMMARY – Definitive Chemoradiotherapy for ESCC

• Definitive chemoradiation is a recommended standard (ESMO 2016)
• Cisplatin-5FU + 50.4 Gy has the best evidence
• No evidence for higher radiation doses
• Salvage surgery for local recurrence is an option
• To be done in highly experienced expert centers, and if possible
• In ongoing phase II/III clinical trials